← Leaderboards
Ira T Lott
University Of California Irvine
$14,129,643
Attributed
$31,667,267
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,667,267 · 10
By mechanism
U01$26,306,436 · 1
R01$3,426,848 · 2
P30$1,792,775 · 2
M01$141,208 · 5
Top collaborators
- Nicole Schupf10 shared
- Wayne P Silverman10 shared
Most similar at University Of California Irvine
Same institution · by research overlap
- Frank M Laferla$22,985,925
- Arthur D Lander$24,994,474
- Haoping Liu$11,091,423
- Christopher C. W. Hughes$22,189,863
- Thomas Lewis Poulos$19,477,156
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainS DiseaseResearch PersonnelDown SyndromeDementiaAmyloidClinical TrialsNeurologicResourcesBiological MarkersCohortInsightS Disease RiskParticipantMagnetic Resonance ImagingImageSamplingScientistNeuropathologyPlasmaOutcome MeasureBlood SpecimenCalifornia
Grant awards (30)
Core H: Down Syndrome Core$432,534
P30 · FY2025 · AG · contact PI
Core H: Down Syndrome Cohort$222,602
P30 · FY2024 · AG · contact PI
Core H: Down Syndrome Cohort$392,500
P30 · FY2023 · AG · contact PI
Core H: Down Syndrome Cohort$272,557
P30 · FY2022 · AG · contact PI
Core H: Down Syndrome Cohort$276,436
P30 · FY2021 · AG · contact PI
Core H: Down Syndrome Cohort$196,146
P30 · FY2020 · AG · contact PI
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$5,747,597
U01 · FY2019 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$355,477
U01 · FY2019 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$5,626,004
U01 · FY2018 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$632,382
U01 · FY2018 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$338,385
U01 · FY2018 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$3,903,529
U01 · FY2017 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$1,725,567
U01 · FY2017 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$3,966,784
U01 · FY2016 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$159,936
U01 · FY2016 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome$3,850,775
U01 · FY2015 · AG
Predicting Cognitive Decline in Adults with Down Syndrome$415,146
R01 · FY2013 · HD · contact PI
Predicting Cognitive Decline in Adults with Down Syndrome$444,189
R01 · FY2012 · HD · contact PI
Predicting Cognitive Decline in Adults with Down Syndrome$452,649
R01 · FY2011 · HD · contact PI
Predicting Cognitive Decline in Adults with Down Syndrome$558,918
R01 · FY2010 · HD · contact PI
AGING AND DEMENTIA IN DOWN SYNDROME$1,381
M01 · FY2010 · RR · contact PI
Predicting Cognitive Decline in Adults with Down Syndrome$452,809
R01 · FY2009 · HD · contact PI
CLINICAL TRIAL: DOWN SYNDROME AND ALZHEIMER DISEASE: ANTIOXIDANT TRIAL$21,661
M01 · FY2008 · RR · contact PI
DIAGNOSIS OF ALZHEIMER DISEASE IN DOWN SYNDROME BY TELEMEDICINE$6,869
M01 · FY2008 · RR · contact PI
DOWN SYNDROME AND ALZHEIMER DISEASE: ANTIOXIDANT TRIAL$37,713
M01 · FY2007 · RR · contact PI
DOWN SYNDROME AND ALZHEIMER DISEASE: ANTIOXIDANT TRIAL$54,658
M01 · FY2006 · RR · contact PI
Alzheimer's Disease in Down Syndrome: Antioxidant Trial$369,610
R01 · FY2005 · AG
DOWN SYNDROME AND ALZHEIMER DISEASE: ANTIOXIDANT TRIAL$18,926
M01 · FY2005 · RR
Alzheimer's Disease in Down Syndrome: Antioxidant Trial$367,388
R01 · FY2004 · AG
Alzheimer's Disease in Down Syndrome: Antioxidant Trial$366,139
R01 · FY2003 · AG